Role of sphingosine kinase/S1P Axis in ECM remodeling of cardiac cells elicited by relaxin

Molecular Endocrinology

Volumn 29, Issue 1, 2015, Pages 53-67

  Frati, Alessia ^a   Ricci, Barbara ^a   Pierucci, Federica ^a   Nistri, Silvia ^a   Bani, Daniele ^a   Meacci, Elisabetta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CERAMIDE; GELATINASE A; GELATINASE B; RELAXIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; 3,3' (1,4 PHENYLENE)BIS[N [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL]ACRYLAMIDE]; 4-(4-FLUOROPHENYL)-2-(4-HYDROXYPHENYL)-5-(4-PYRIDYL)IMIDAZOLE; ANILINE DERIVATIVE; BENZYLIDENE DERIVATIVE; FLAVONOID; IMIDAZOLE DERIVATIVE; LYSOPHOSPHOLIPID; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOTRANSFERASE; PYRIDINE DERIVATIVE; SMALL INTERFERING RNA; SPHINGOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL LABELING; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEART MUSCLE CELL; MOUSE; MULTIGENE FAMILY; NEWBORN; NONHUMAN; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPHINGOLIPID METABOLISM; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; ENZYME ACTIVATION; GENETICS; METABOLISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

RATTUS;

ANILINE COMPOUNDS; ANIMALS; BENZYLIDENE COMPOUNDS; CELL PROLIFERATION; CELLS, CULTURED; CERAMIDES; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FLAVONOIDS; IMIDAZOLES; LYSOPHOSPHOLIPIDS; MATRIX METALLOPROTEINASES; MICE; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRIDINES; RATS; RELAXIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOSINE;

EID: 84922309570     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1201     Document Type: Article

References (65)

1. Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol. 2010;6:489-497.
2. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res. 2009;50:S91-S96.
3. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1- phosphate signaling and its role in disease. Trends Cell Biol. 2012; 22:50-60.
4. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139- 150.
5. Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1-23.
6. Wu WT, Chen CN, Lin CI, Chen JH, Lee H. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology. 2005;146:3387-3400.
7. Annabi B, Thibeault S, Lee YT, et al. Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Exp Hematol. 2003;31:640- 649.
8. Buisson-Legendre N, Bernard P, Bobichon H, et al. Involvement of the 92-kDa gelatinase (matrix metalloproteinase-9) in the ceramidemediated inhibition of human keratinocyte growth. Biochem Biophys Res Commun. 1999;260:634-640.
9. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87:1285-1342.
10. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T. Matrix metalloproteinase- 9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
11. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007;47:211-242.
12. Matsumoto Y, Park IK, Kohyama K. Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy. J Immunol. 2009;183:4773-4781.
13. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005;115:599-609.
14. Samuel CS, Lekgabe ED, Mookerjee I. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease. Adv Exp Med Biol. 2007;612:88-103.
15. Nistri S, Pini A, Sassoli C, et al. Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration. J Cell Mol Med. 2012;16:507-519.
16. Wilkinson TN, Speed TP, Tregear GW, Bathgate RA. Evolution of the relaxin-like peptide family. BMC Evol Biol. 2005;5:14.
17. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest. 1996;98:2739-2745.
18. Samuel CS, Royce SG, Chen B, et al. Relaxin family peptide receptor- 1 protects against airway fibrosis during homeostasis but not against fibrosis associated with chronic allergic airways disease. Endocrinology. 2009;150:1495-1502.
19. Heeg MH, Koziolek MJ, Vasko R, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 2005;68:96-109.
20. Mookerjee I, Hewitson TD, Halls ML, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009;23:1219-1229.
21. Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 2001;15:2187- 2195.
22. Nistri S, Bigazzi M, Bani D. Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises. Cardiovasc Hematol Agents Med Chem. 2007;5:101-108.
23. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2010;7:48-58.
24. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc Res. 2003;57:395-404.
25. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429-1439.
26. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7:75-82.
27. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev. 2012;92:635-688.
28. Perbal B. CCN proteins: A centralized communication network. J Cell Commun Signal. 2013;7:169-177.
29. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf). 2009;195:321-338.
30. Formigli L, Perna AM, Meacci E, et al. Paracrine effects of transplantated myoblasts and relaxin on post-infarction heart remodelling. J Cell Mol Med. 2007;11:1087-1100.
31. Airola MV, Hannun YA. Sphingolipid metabolism and neutral sphingomyelinases. Handb Exp Pharmacol. 2013;215:57-76.
32. Luberto C, Hassler DF, Signorelli P, et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem. 2002;277:41128-41139.
33. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003; 63:5962-5969.
34. Kleinjan A, van Nimwegen M, Leman K, Hoogsteden HC, Lambrecht BN. Topical treatment targeting sphingosine-1-phosphate and sphingosine lyase abrogates experimental allergic rhinitis in a murine model. Allergy. 2013;68:204-212.
35. Meacci E, Nuti F, Donati C, Cencetti F, Farnararo M, Bruni P. Sphingosine kinase activity is required for myogenic differentiation of C2C12 myoblasts. J Cell Physiol. 2008;214:210-220.
36. Sassoli C, Formigli L, Squecco R, Zecchi-Orlandini S, Francini F, Meacci E. Effects of S1P on skeletal muscle repair/regeneration during eccentric contraction. J Cell Mol Med. 2010;10:1111-1125.
37. Meacci E, Bini F, Battistini C. Sphingosine-1-phosphate signaling in skeletal muscle cells. Methods Mol Biol. 2012;876:155-165.
38. De Palma C, Meacci E, Perrotta C, Bruni P, Clementi E. Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through receptors: a novel pathway relevant to the pathophysiology of endothelium neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate. Arterioscler Thromb Vasc Biol. 2006;26:99-105.
39. Formigli L, Sassoli C, Squecco R, Zecchi-Orlandini S, Francini F, Meacci E. Regulation of transient receptor potential channel 1 (TRPC1) by sphingosine-1-phosphate in C2C12 myoblasts and its relevance for a role of mechanotransduction in skeletal muscle differentiation. J Cell Sci. 2009;122(Pt 9):1322-1333.
40. Meacci E, Bini F, Sassoli C, et al. Functional interaction between TRPC1 channel and connexin-43 protein: a novel pathway underlying S1P action on skeletal myogenesis. Cell Mol Life Sci. 2010; 67:4269-4285.
41. Squecco R, Sassoli C, Nuti F, et al. Sphingosine 1-phosphate induces myoblast differentiation through Cx43 protein expression: a role for a gap junction-dependent and -independent function. Mol Biol Cell. 2006;17:4896-4910.
42. 3 and its structural analogues in human neuroblastoma cells. A role for ceramide kinase/ceramide 1-phosphate axis. Neuropharmacology. 2012;63: 524-537.
43. Lucki NC, Sewer MB. The interplay between bioactive sphingolipids and steroid hormones. Steroids. 2010;75:390-399.
44. Formigli L, Zecchi-Orlandini S, Meacci E, Bani D. Skeletal myoblasts for heart regeneration and repair: state of the art and perspectives on the mechanisms for functional cardiac benefits. Curr Pharm Des. 2010;16:915-928.
45. Chow BS, Chew EG, Zhao C, Bathgate RA, Hewitson TD, Samuel CS. Relaxin signals through a RXFP1 pERK-nNOS-NO-cGMPdependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS One. 2012;7:e42714.
46. Ahmad N, Wang W, Nair R, Kapila S. Relaxin induces matrixmetalloproteinases- 9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways. Mol Cell Endocrinol. 2012;363:46-61.
47. Bani D, Bigazzi M. Relaxin as a cardiovascular drug: a promise kept. Curr Drug Saf. 2011;6:324-328.
48. Devic E, Xiang Y, Gould D, Kobilka B. Beta-adrenergic receptor subtype-specific signaling in cardiac myocytes from beta(1) and beta (2) adrenoceptor knockout mice. Mol Pharmacol. 2001;60: 577-583.
49. van der Westhuizen ET, Halls ML, Samuel CS, et al. Relaxin family peptide receptors-from orphans to therapeutic targets. Drug Discov Today. 2008;13:640-651.
50. Zhao L, Roche PJ, Gunnersen JM, et al. Mice without a functional relaxin gene are unable to deliver milk to their pups. Endocrinology. 1999;140:445-453.
51. Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension. 2005;46:412-418.
52. Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev. 2013;93:405-480
53. Halls ML, Papaioannou M, Wade JD, Evans BA, Bathgate RA, Summers RJ. RXFP1 couples to the Galpha-Gbetagamma-PI3KPKCzeta pathway via the final 10 amino acids of the receptor Cterminal tail. Ann N Y Acad Sci. 2009;1160:117-120.
54. Knapp M, Baranowski M, Czarnowski D, et al. Plasma sphingosine- 1-phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit. 2009;15:CR490-CR493.
55. Takuwa N, Ohkura S, Takashima S, et al. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res. 2010;85:484-493.
56. Gomez L, Paillard M, Price M, Chen Q, Teixeira G, Spiegel S, Lesnefsky EJ. A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during cardioprotection, Basic Res Cardiol. 2011;106:1341- 1353.
57. Schwalm S, Pfeilschifter J, Huwiler A. Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases. Biochim Biophys Acta. 2013;1831:239-250.
58. Matsui Y, Sadoshima J. Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy. J Mol Cell Cardiol. 2004;37:477-481.
59. Katsuma S, Hada Y, Shiojima S, et al. Transcriptional profiling of gene expression patterns during sphingosine 1-phosphate-induced mesangial cell proliferation. Biochem Biophys Res Commun. 2003; 300:577-584.
60. Meacci E, Cencetti F, Donati C, et al. Down-regulation of EDG5/ S1P2 during myogenic differentiation results in the specific uncoupling of sphingosine 1-phosphate signalling to phospholipase D. Biochim Biophys Acta. 2003;1633:133-142.
61. + current in guineapig atrial myocytes by sphingosine-1-phosphate. J Physiol. 1995; 489:701-707.
62. Gellings Lowe N, Swaney JS, Moreno KM, Sabbadini RA. Sphingosine- 1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc Res. 2009;82:303-312.
63. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol. 2010;43:662-673.
64. Ikeda H, Ohkawa R, Watanabe N, et al. Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. Clin Chim Acta. 2010;411:765- 770.
65. Waeber C, Walther T. Sphingosine-1-phosphate as a potential target for the treatment of myocardial infarction. Circ J. 2014;78:795- 802.